A drug poster with no competitor on the page: what four AIs found in Novartis's remibrutinib data

Novartis's REMIX poster benchmarks its new CSU drug against placebo alone — naming no rival therapy, no liver-enzyme breakdown, and skipping a 12-fold safety signal. A four-model panel mapped the gaps a single model missed.